APS 4010 Module 1 Written Assignment: A Technologist Leading the Launch of Radioligand Therapy Example

Leading Without the Title: A Lead Technologist's Role in Launching Radioligand Therapy at a Community Hospital

Student Name

B.S. in Nuclear Medicine Technology, Thomas Edison State University

APS-4010: Current Trends and Applications in Applied Science and Technology

Mentor Name

Month Day, Year

Leading Without the Title: A Lead Technologist's Role in Launching Radioligand Therapy at a Community Hospital

Introduction

In most hospitals, new technology is chosen by physicians and administrators, but it succeeds or fails in the hands of the staff who use it every day. Nuclear medicine is about to test that idea. Our community hospital in central New Jersey plans to begin treating patients with lutetium-177 radioligand therapy within a year. As the department's lead technologist, I have no authority to hire or set budgets, yet I will be responsible for much of what makes the program work. This assignment examines that leadership role and introduces the technology this course project will follow.

The Technology

Radioligand therapy pairs a radioactive atom with a molecule that seeks a target on cancer cells. Lutetium-177 emits beta particles that damage nearby cells over a short range and gamma rays that allow imaging. Two products have changed practice. For metastatic castration-resistant prostate cancer, lutetium-177 attached to a molecule targeting prostate-specific membrane antigen (PSMA) was tested in the VISION trial. Sartor et al. (2021) reported that adding it to standard care improved overall survival, with a median of 15.3 months compared with 11.3 months for standard care alone, and lengthened the time before the disease progressed on imaging. For certain neuroendocrine tumors, lutetium-177 dotatate improved progression-free survival in the NETTER-1 trial (Strosberg et al., 2017). Both treatments are now approved in the United States, and patients are selected with PET imaging that shows whether their tumors carry the target.

What a Technical Leader Needs

A technical leader needs three kinds of knowledge. The first is technical: radiopharmaceutical handling, dose verification, imaging after treatment and radiation safety. The second is procedural: how a new treatment moves from order to administration to patient release, and where errors can occur. The third is relational: how to bring together oncologists, radiation safety staff, nurses, pharmacy and schedulers who have never worked on a therapy like this together.

Leading Team Learning

Edmondson et al. (2001) studied hospitals adopting a new form of minimally invasive cardiac surgery and found that success depended less on the surgeons' skill or the hospital's resources than on how teams learned together. In the successful hospitals, leaders treated the new procedure as something the whole team had to learn together, picked team members on purpose, held practice sessions and made it safe to speak up about problems. Where teams handled it as just another routine bolted onto old ones, they struggled.

That finding fits a technologist's position. I cannot assign people to the therapy team, but I can propose who should be on it, organize dry runs before the first patient and set the tone that anyone may stop a procedure if something looks wrong. I can also frame the therapy as new work for everyone, since radioligand therapy changes routines in every department it touches.

Specific Leadership Tasks

The Course Project

Each written assignment in this course builds on the previous one, and the four together become the final project. This first part defines the technology and my leadership role. The next will examine the technology's impact on patients, staff and the department, the third will look at it from different stakeholders' perspectives and the last will place it within the trends shaping nuclear medicine.

Conclusion

Technical leadership in health care often belongs to people without formal authority. For radioligand therapy at our hospital, the lead technologist's job is to turn trial evidence into a safe, practiced routine by leading the team's learning, the protocols and the communication that make a new technology work.

References

Edmondson, A. C., Bohmer, R. M., & Pisano, G. P. (2001). Disrupted routines: Team learning and new technology implementation in hospitals. Administrative Science Quarterly, 46(4), 685-716. https://doi.org/10.2307/3094828

Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., Park, C. H., Beer, T. M., Armour, A., Pérez-Contreras, W. J., DeSilvio, M., Kpamegan, E., Gericke, G., Messmann, R. A., Morris, M. J., & Krause, B. J. (2021). Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. New England Journal of Medicine, 385(12), 1091-1103. https://doi.org/10.1056/NEJMoa2107322

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., Bushnell, D., O'Dorisio, T. M., Baum, R. P., Kulkarni, H. R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., ... Krenning, E. (2017). Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. New England Journal of Medicine, 376(2), 125-135. https://doi.org/10.1056/NEJMoa1607427